Jain Sidhant, Vimal Neha, Angmo Nilza, Sengupta Madhumita, Thangaraj Suraj
Independent Researcher, Institute for Globally Distributed Open Research and Education (IGDORE), Rewari, India.
Bhaskaracharya College of Applied Sciences, University of Delhi, Delhi, India.
Immunol Invest. 2023 Nov;52(8):1096-1149. doi: 10.1080/08820139.2023.2280698. Epub 2023 Nov 24.
Dengue is an infectious disease caused by dengue virus (DENV) and is a serious global burden. Antibody-dependent enhancement and the ability of DENV to infect immune cells, along with other factors, lead to fatal Dengue Haemorrhagic Fever and Dengue Shock Syndrome. This necessitates the development of a robust and efficient vaccine but vaccine development faces a number of hurdles. In this review, we look at the epidemiology, genome structure and cellular targets of DENV and elaborate upon the immune responses generated by human immune system against DENV infection. The review further sheds light on various challenges in development of a potent vaccine against DENV which is followed by presenting a current account of different vaccines which are being developed or have been licensed.
登革热是由登革病毒(DENV)引起的一种传染病,是严重的全球负担。抗体依赖增强作用以及DENV感染免疫细胞的能力,与其他因素一起,导致致命的登革出血热和登革休克综合征。这就需要研发一种强大而有效的疫苗,但疫苗研发面临诸多障碍。在这篇综述中,我们研究了DENV的流行病学、基因组结构和细胞靶点,并详细阐述了人类免疫系统针对DENV感染产生的免疫反应。该综述进一步阐明了研发针对DENV的有效疫苗所面临的各种挑战,随后介绍了正在研发或已获许可的不同疫苗的现状。